Skip to main content
AAN.com
Articles
September 26, 2005

Vascular events, mortality, and preventive therapy following ischemic stroke in the elderly

This article has been corrected.
VIEW CORRECTION
September 27, 2005 issue
65 (6) 835-842

Abstract

Background: The authors studied mortality, vascular events, and preventive therapies following ischemic stroke among adults aged ≥65 years.
Methods: The authors identified 546 subjects with first ischemic stroke during 1989 to 2001 among Cardiovascular Health Study participants. Deaths, recurrent strokes, and coronary heart disease (CHD) events were identified over 3.2 years (median) follow-up.
Results: During the first year of follow-up, rates were 105.4/1,000 for recurrent stroke and 59.3/1,000 for CHD. After the first year, the stroke rate was 52.0/1,000 and the CHD rate was 46.5/1,000. Cardioembolic strokes had the highest mortality (185.4/1,000) and recurrence rates (86.6/1,000). Lacunar strokes had the lowest mortality (119.3/1,000) and recurrence rates (43.0/1,000). Age and male sex predicted death and CHD, but not recurrence. Outcomes did not differ by race. Following stroke, 47.8% used aspirin and 13.5% used other antiplatelet agents; 52.6% of patients with atrial fibrillation used warfarin; 31.3% of hyperlipidemic subjects, 57.0% of diabetic patients, and 81.5% of hypertensive patients were drug-treated; and 40.0% of hypertensive patients had blood pressure (BP) <140/90 mm Hg. Older subjects were less likely to use lipid-lowering therapy, women were less likely to have BP <140/90 mm Hg, and low-income subjects were less likely to use diabetes medications.
Conclusions: Recurrent strokes were nearly twice as frequent as coronary heart disease (CHD) events during the first year after initial stroke, but stroke and CHD rates were similar after the first year. Preventive drug therapies were underused, which may reflect clinical uncertainty due to the lack of clinical trials among the elderly. Utilization was lower among the oldest patients, women, and low-income individuals.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (e1.gif)
File (e2.doc)
File (e3.doc)
File (e4.doc)

References

1.
Muntner P, Garrett E, Klag MJ, Coresh J. Trends in stroke prevalence between 1973 and 1991 in the US population 25 to 74 years of age. Stroke 2002;33:1209–1213.
2.
American Heart Association. Heart disease and stroke statistics—2004 update. American Heart Association, 2004.
3.
Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004;62:569–573.
4.
Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in isch-emic stroke subtypes: a population-based study. Stroke 2001;32:2735–2740.
5.
Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994;44:626–634.
6.
Hillen T, Coshall C, Tilling K, Rudd AG, McGovern R, Wolfe CD. Cause of stroke recurrence is multifactorial: patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke 2003;34:1457–1463.
7.
Petty GW, Brown RD, Jr., Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 2000;31:1062–1068.
8.
Dexter DD, Jr., Whisnant JP, Connolly DC, O'Fallon WM. The association of stroke and coronary heart disease: a population study. Mayo Clin Proc 1987;62:1077–1083.
9.
Vickrey BG, Rector TS, Wickstrom SL, et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 2002;33:901–906.
10.
Adams RJ, Chimowitz MI, Alpert JS, et al. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Stroke 2003;34:2310–2322.
11.
Glader EL, Stegmayr B, Norrving B, et al. Sex differences in management and outcome after stroke: a Swedish national perspective. Stroke 2003;34:1970–1975.
12.
Hillen T, Dundas R, Lawrence E, Stewart JA, Rudd AG, Wolfe CD. Antithrombotic and antihypertensive management 3 months after ischemic stroke: a prospective study in an inner city population. Stroke 2000;31:469–475.
13.
Mouradian MS, Majumdar SR, Senthilselvan A, Khan K, Shuaib A. How well are hypertension, hyperlipidemia, diabetes, and smoking managed after a stroke or transient ischemic attack? Stroke 2002;33:1656–1659.
14.
Tu JV, Gong Y. Trends in treatment and outcomes for acute stroke patients in Ontario, 1992-1998. Arch Intern Med 2003;163:293–297.
15.
Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991;1:263–276.
16.
Furberg CD, Manolio TA, Psaty BM, et al. Major electrocardiographic abnormalities in persons aged 65 years and older (the Cardiovascular Health Study). Cardiovascular Health Study Collaborative Research Group. Am J Cardiol 1992;69:1329–1335.
17.
Psaty BM, Lee M, Savage PJ, Rutan GH, German PS, Lyles M. Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. The Cardiovascular Health Study Collaborative Research Group. J Clin Epidemiol 1992;45:683–692.
18.
Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 1995;41:264–270.
19.
Ives DG, Fitzpatrick AL, Bild DE, et al. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. Ann Epidemiol 1995;5:278–285.
20.
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265:3255–3264.
21.
Longstreth WT, Jr., Bernick C, Fitzpatrick A, et al. Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health Study. Neurology 2001;56:368-375.
22.
Meissner I, Whisnant JP, Garraway WM. Hypertension management and stroke recurrence in a community (Rochester, Minnesota, 1950–1979). Stroke 1988;19:459–463.
23.
Chimowitz MI, Poole RM, Starling MR, Schwaiger M, Gross MD. Frequency and severity of asymptomatic coronary disease in patients with different causes of stroke. Stroke 1997;28:941–945.
24.
Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 1999;354:1457–1463.
25.
Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 2001;119:194S–206S.
26.
Brophy MT, Snyder KE, Gaehde S, Ives C, Gagnon D, Fiore LD. Anticoagulant use for atrial fibrillation in the elderly. J Am Geriatr Soc 2004;52:1151–1156.
27.
Holroyd-Leduc JM, Kapral MK, Austin PC, Tu JV. Sex differences and similarities in the management and outcome of stroke patients. Stroke 2000;31:1833–1837.
28.
Rigler SK, Webb MJ, Patel AT, Lai SM, Duncan PW. Use of antihypertensive and antithrombotic medications after stroke in community-based care. Ann Pharmacother 2001;35:811–816.
29.
Post-stroke antihypertensive treatment study. A preliminary result. PATS Collaborating Group. Chin Med J (Engl) 1995;108:710–717.
30.
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033–1041.
31.
Carswell JL, Beard KA, Chevrette MM, Pardue CN, Hess DC, Fagan SC. Tracking trends in secondary stroke prevention strategies. Ann Pharmacother 2004;38:215–219.
32.
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–3421.
33.
Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623–1630.
34.
Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757–767.
35.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703–713.

Information & Authors

Information

Published In

Neurology®
Volume 65Number 6September 27, 2005
Pages: 835-842

Publication History

Published online: September 26, 2005
Published in print: September 27, 2005

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

R. C. Kaplan, PhD
From the Department of Epidemiology and Population Health (Dr. Kaplan), Albert Einstein College of Medicine, Bronx, NY; Departments of Neurology (Drs. Tirschwell and Longstreth), Epidemiology (Drs. Longstreth, Heckbert, and Psaty), Medicine (Dr. Psaty), and Health Services (Dr. Psaty), University of Washington, Seattle; Epidemiology and Biometry Program (Dr. Manolio), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Department of Neurology (Dr. Lefkowitz), Wake Forest University School of Medicine, Winston-Salem, NC; and Department of Epidemiology (Dr. El-Saed), University of Pittsburgh.
D. L. Tirschwell, MD
From the Department of Epidemiology and Population Health (Dr. Kaplan), Albert Einstein College of Medicine, Bronx, NY; Departments of Neurology (Drs. Tirschwell and Longstreth), Epidemiology (Drs. Longstreth, Heckbert, and Psaty), Medicine (Dr. Psaty), and Health Services (Dr. Psaty), University of Washington, Seattle; Epidemiology and Biometry Program (Dr. Manolio), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Department of Neurology (Dr. Lefkowitz), Wake Forest University School of Medicine, Winston-Salem, NC; and Department of Epidemiology (Dr. El-Saed), University of Pittsburgh.
W. T. Longstreth, Jr, MD, MPH
From the Department of Epidemiology and Population Health (Dr. Kaplan), Albert Einstein College of Medicine, Bronx, NY; Departments of Neurology (Drs. Tirschwell and Longstreth), Epidemiology (Drs. Longstreth, Heckbert, and Psaty), Medicine (Dr. Psaty), and Health Services (Dr. Psaty), University of Washington, Seattle; Epidemiology and Biometry Program (Dr. Manolio), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Department of Neurology (Dr. Lefkowitz), Wake Forest University School of Medicine, Winston-Salem, NC; and Department of Epidemiology (Dr. El-Saed), University of Pittsburgh.
T. A. Manolio, MD, PhD
From the Department of Epidemiology and Population Health (Dr. Kaplan), Albert Einstein College of Medicine, Bronx, NY; Departments of Neurology (Drs. Tirschwell and Longstreth), Epidemiology (Drs. Longstreth, Heckbert, and Psaty), Medicine (Dr. Psaty), and Health Services (Dr. Psaty), University of Washington, Seattle; Epidemiology and Biometry Program (Dr. Manolio), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Department of Neurology (Dr. Lefkowitz), Wake Forest University School of Medicine, Winston-Salem, NC; and Department of Epidemiology (Dr. El-Saed), University of Pittsburgh.
S. R. Heckbert, MD, PhD
From the Department of Epidemiology and Population Health (Dr. Kaplan), Albert Einstein College of Medicine, Bronx, NY; Departments of Neurology (Drs. Tirschwell and Longstreth), Epidemiology (Drs. Longstreth, Heckbert, and Psaty), Medicine (Dr. Psaty), and Health Services (Dr. Psaty), University of Washington, Seattle; Epidemiology and Biometry Program (Dr. Manolio), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Department of Neurology (Dr. Lefkowitz), Wake Forest University School of Medicine, Winston-Salem, NC; and Department of Epidemiology (Dr. El-Saed), University of Pittsburgh.
D. Lefkowitz, MD
From the Department of Epidemiology and Population Health (Dr. Kaplan), Albert Einstein College of Medicine, Bronx, NY; Departments of Neurology (Drs. Tirschwell and Longstreth), Epidemiology (Drs. Longstreth, Heckbert, and Psaty), Medicine (Dr. Psaty), and Health Services (Dr. Psaty), University of Washington, Seattle; Epidemiology and Biometry Program (Dr. Manolio), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Department of Neurology (Dr. Lefkowitz), Wake Forest University School of Medicine, Winston-Salem, NC; and Department of Epidemiology (Dr. El-Saed), University of Pittsburgh.
A. El-Saed, MD
From the Department of Epidemiology and Population Health (Dr. Kaplan), Albert Einstein College of Medicine, Bronx, NY; Departments of Neurology (Drs. Tirschwell and Longstreth), Epidemiology (Drs. Longstreth, Heckbert, and Psaty), Medicine (Dr. Psaty), and Health Services (Dr. Psaty), University of Washington, Seattle; Epidemiology and Biometry Program (Dr. Manolio), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Department of Neurology (Dr. Lefkowitz), Wake Forest University School of Medicine, Winston-Salem, NC; and Department of Epidemiology (Dr. El-Saed), University of Pittsburgh.
B. M. Psaty, MD, PhD
From the Department of Epidemiology and Population Health (Dr. Kaplan), Albert Einstein College of Medicine, Bronx, NY; Departments of Neurology (Drs. Tirschwell and Longstreth), Epidemiology (Drs. Longstreth, Heckbert, and Psaty), Medicine (Dr. Psaty), and Health Services (Dr. Psaty), University of Washington, Seattle; Epidemiology and Biometry Program (Dr. Manolio), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Department of Neurology (Dr. Lefkowitz), Wake Forest University School of Medicine, Winston-Salem, NC; and Department of Epidemiology (Dr. El-Saed), University of Pittsburgh.

Notes

Address correspondence and reprint requests to Dr. Robert C. Kaplan, Department of Epidemiology and Population Health, Belfer Building, Room 1303A, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461; e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Prognosis of ischemic stroke predicted by machine learning based on multi-modal MRI radiomics, Frontiers in Psychiatry, 13, (2023).https://doi.org/10.3389/fpsyt.2022.1105496
    Crossref
  2. Caring for Patients With Diabetes in Stroke Neurology, Stroke, 54, 3, (894-904), (2023).https://doi.org/10.1161/STROKEAHA.122.038163
    Crossref
  3. Pharmacological therapy in the secondary prevention of ischemic stroke in the oldest-old patients: has it improved in recent decades?, Revista Clínica Española (English Edition), 223, 4, (202-208), (2023).https://doi.org/10.1016/j.rceng.2023.02.006
    Crossref
  4. Terapia farmacológica en la prevención secundaria del ictus isquémico en los muy ancianos: ¿ha mejorado en las últimas décadas?, Revista Clínica Española, 223, 4, (202-208), (2023).https://doi.org/10.1016/j.rce.2023.01.003
    Crossref
  5. Factors affecting self-reported bleeding acceptance in acute ischemic stroke survivors on various types of antithrombotic therapy, Journal of Stroke and Cerebrovascular Diseases, 32, 1, (106894), (2023).https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106894
    Crossref
  6. The efficacy of STA-MCA double anastomosis comparing to single anastomosis in chronic internal carotid artery occlusion patients, Clinical Neurology and Neurosurgery, 233, (107947), (2023).https://doi.org/10.1016/j.clineuro.2023.107947
    Crossref
  7. Acetylglutamine Differentially Associated with First-Time Versus Recurrent Stroke, Translational Stroke Research, (2023).https://doi.org/10.1007/s12975-023-01181-1
    Crossref
  8. Stroke Therapeutics in the Care of Older Persons, Optimizing Pharmacotherapy in Older Patients, (349-367), (2023).https://doi.org/10.1007/978-3-031-28061-0_24
    Crossref
  9. Triglyceride-glucose index and stroke recurrence in elderly patients with ischemic stroke, Frontiers in Endocrinology, 13, (2022).https://doi.org/10.3389/fendo.2022.1005614
    Crossref
  10. Racial Disparities in Stroke Recurrence, Neurology, 99, 22, (e2464-e2473), (2022)./doi/10.1212/WNL.0000000000201225
    Abstract
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share